Tarsus Pharmaceuticals (TARS) Total Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Total Liabilities history runs 8 years deep, the most recent figure standing at $232.2 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 46.68% year-over-year to $232.2 million; the TTM figure through Mar 2026 stood at $232.2 million (up 46.68% YoY), while the FY2025 annual figure was $218.7 million, up 43.47% from the prior year.
• Total Liabilities was $232.2 million for Q1 2026 at Tarsus Pharmaceuticals, up from $218.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $232.2 million in Q1 2026 to a low of $31.3 million in Q2 2022.
• Historically, Total Liabilities has averaged $105.6 million across 5 years, with a median of $74.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities advanced 17.11% in 2023, then surged 202.44% in 2024.
• A 5-year view of Total Liabilities shows it stood at $35.0 million in 2022, then soared by 95.93% to $68.5 million in 2023, then surged by 122.56% to $152.5 million in 2024, then soared by 43.47% to $218.7 million in 2025, then advanced by 6.15% to $232.2 million in 2026.
• The last three Total Liabilities figures came in at $232.2 million (Q1 2026), $218.7 million (Q4 2025), and $199.5 million (Q3 2025), per Business Quant data.